- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01022853
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 in Combination With Oral BIBF 1120 in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Ancona, Italy
- 1230.7.39002 Boehringer Ingelheim Investigational Site
-
Milano, Italy
- 1230.7.39001 Boehringer Ingelheim Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- Patients with confirmed diagnosis of advanced, non resectable and/or metastatic solid tumours, who have failed conventional treatment, and for whom no therapy of proven efficacy exists, or who are not amenable to established forms of treatment
- Age > or = 18 years
- European Cooperative Oncology Group performance status < or = 2
- Written informed consent in accordance with International Conference on Harmonization -Good Clinical Practice (ICH-GCP) and local legislation
- Recovery from Common Terminology Criteria for Adverse Events grade 2-4 therapy-related toxicities from previous systemic anti-cancer therapies or radiotherapy (except alopecia)
Exclusion criteria:
- Serious illness or concomitant non-oncological disease considered by the investigator to be incompatible with the trial
- Known hypersensitivity to the trial drugs or their excipients
- Treatment with any other investigational drug or participation in any other interventional trial within 28 days before first administration of trial drug (BIBF 1120) or concomitantly with this trial
- Systemic anti-cancer therapy or radiotherapy within 28 days before start of therapy or concomitantly with this trial. The restriction does not apply to steroids and bisphosphonates
- Active infectious disease infection or HIV I/II
- Other malignancy currently requiring another anti-cancer therapy
- Clinical evidence of symptomatic progressive brain or leptomeningeal disease during the past 6 months
- Known inherited predisposition to bleeding or thrombosis
- Radiographic evidence of cavitary or necrotic tumours
- History of clinically significant haemoptysis within the past 3 months
- Centrally located tumours with radiographic evidence (Computed Tomography or Magnetic Resonance Imaging) of local invasion of major blood vessels
- Absolute Neutrophil Count (ANC) less than 1.5 x 1000000000/L
- Platelets Count (PLT) less than 100 x 1000000000/L
- Total bilirubin > upper limit of normal (ULN)
- Alaninaminotransferase (ALT) and/or Aspartateaminotransferase (AST) >= 1.5 x ULN (in case of liver metastases: ALT and AST >= 2.5 x ULN)
- Serum creatinine > 1.5 mg/dl
- Major injuries and/or surgery or bone fracture within 28 days before first administration of trial drug (BIBF 1120), or planned surgical procedures during the trial period
- Known history of clinically relevant QT prolongation (e.g. long QT syndrome)
- History of severe haemorrhagic or thromboembolic event in the past 6 months (excluding central venous catheter thrombosis and peripheral deep vein thrombosis)
- Therapeutic anticoagulation (except low dose heparin and/or heparin flush as needed for maintenance of an indwelling intravenous device) or antiplatelet therapy (except for chronic low-dose therapy with acetylsalicylic acid < or = 325mg per day)
- Active alcohol or drug abuse
- Women and men who are sexually active and unwilling to use a medically acceptable method of contraception during the trial
- Pregnancy or breast-feeding
- Patients unable to comply with the protocol
- Uncontrolled hypertension
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: BIBF 1120 and BI 6727
Finding Maximum Tolerated Dose of BI 6727 in combination with BIBF 1120
|
intravenous each 21 days
oral continuously
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD).
Time Frame: 28 days
|
DLT was defined as:
|
28 days
|
Maximum Tolerated Dose (MTD) of Volasertib in Combination With Nintedanib
Time Frame: 28 days
|
The MTD was determined using a 3+3 design with de-escalation.
The MTD was defined as the highest dose level at which maximal 1 out of 6 patients experienced DLT in the first course of the escalation nd de-escalation phase.
However, all DLT's occurring in the trial were considered for selection of the recommended dose for further development.
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Drug Related Adverse Events
Time Frame: From first study drug administration until 28 days after the last administration of any study medication, up to 485 days
|
Number of participants with investigator-defined drug related adverse events.
|
From first study drug administration until 28 days after the last administration of any study medication, up to 485 days
|
Number of Participants With Dose Limiting Toxicities
Time Frame: From first study drug administration until 28 days after the last administration of any study medication, up to 485 days
|
Number of participants with dose limiting toxicities (DLTs). DLT was defined as:
|
From first study drug administration until 28 days after the last administration of any study medication, up to 485 days
|
Cmax of Volasertib
Time Frame: 0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion
|
Maximum measured concentration (Cmax) in plasma of Volasertib in Cycle 1.
|
0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion
|
CL of Volasertib
Time Frame: 0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion
|
Total plasma Clearance (CL) of Volasertib in Cycle 1.
|
0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion
|
Vss of Volasertib
Time Frame: 0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion
|
Volume of distribution at steady state (Vss) of Volasertib in Cycle 1.
|
0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion
|
Cmax of Nintedanib
Time Frame: 5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9
|
Maximum measured concentration (Cmax) of Nintedanib in Cycle 1. 400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient. |
5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9
|
AUC(0-6h) of Nintedanib
Time Frame: 5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9
|
Area under the concentration-time curve (AUC) of Nintedanib over the time interval 0 to 6 hours in Cycle 1. 400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient. |
5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9
|
Tmax of Nintedanib
Time Frame: 5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9
|
Time from dosing to the maximum measured concentration, Cmax, of Nintedanib (tmax) in Cycle 1. 400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient. |
5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9
|
Number of Patients With Best Overall Response
Time Frame: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
|
Best overall response based on response evaluation criteria in solid tumors (RECIST) version 1.1.
Best overall response is defined as the best overall response (complete response, partial response, stable disease, progressive disease or not evaluable) since the start of treatment.
|
Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
|
Number of Patients With Objective Response (OR)
Time Frame: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
|
Objective tumor response based on response evaluation criteria in solid tumors (RECIST) version 1.1.
OR is defined as complete response (CR) or partial response (PR) as best response throughout the study.
|
Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
|
Number of Patients With Disease Control
Time Frame: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
|
Disease control based on response evaluation criteria in solid tumors (RECIST) version 1.1.
Disease control is defined as complete response (CR), partial response (PR) or stable disease (SD) as best response throughout the study.
|
Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
|
Duration of Disease Control
Time Frame: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
|
Disease control based on response evaluation criteria in solid tumors (RECIST) version 1.1.
Patients who had a best overall tumour response of complete response (CR), partial response (PR) or stable disease (SD) were assessed to show disease control.
|
Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
|
Progression Free Survival (PFS)
Time Frame: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
|
PFS is defined as the time from start of treatment with study medication to tumour progression or death whichever occurs first.
Tumour response was to be documented using appropriate techniques such as magnetic resonance imaging (MRI) or computer tomography (CT).
|
Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1230.7
- 2008-008304-41 (EudraCT Number: EudraCT)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
John M. BuattiNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedUterine Cervical Neoplasms | Prostatic Neoplasms | Rectal Neoplasms | Endometrial Neoplasms | Anus NeoplasmsUnited States
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
GlaxoSmithKlineRecruitingColonic Neoplasms | Neoplasms, ColonUnited States, Finland, France, Italy, Japan, Netherlands, Norway, Spain, Taiwan, United Kingdom, Australia, Belgium, Brazil, Germany, Greece, Sweden, Turkey, Canada, Korea, Republic of, Argentina, Hungary, Estonia, Portugal, Mexico, Pa...
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong
Clinical Trials on BI 6727
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedNeoplasmsUnited States, Taiwan
-
Boehringer IngelheimCompleted
-
Northwestern UniversityNational Cancer Institute (NCI); National Comprehensive Cancer NetworkWithdrawnRecurrent Adult Acute Lymphoblastic Leukemia | Refractory Adult Acute Lymphoblastic LeukemiaUnited States
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedCarcinoma, Non-Small-Cell LungBahamas, Canada
-
University of AlbertaWithdrawnLeukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Acute | Leukemia, Monocytic, Acute | Leukemia, Megakaryoblastic, Acute | Leukemia, Erythroblastic, AcuteCanada
-
Boehringer IngelheimCompleted